Erythromycin versus metoclopramide for post-pyloric spiral nasoenteric tube placement: a randomized non-inferiority trial

Bei Hu1, Xin Ouyang2, Liming Lei1, Cheng Sun3, Ruibin Chi4, Jian Guo5, Wenlong Guo6, Yanlin Zhang7, Yong Li8, Daoyong Huang9, Huafeng Sun10, Zhiqiang Nie11, Jieyang Yu5, Yuan Zhou6, Hao Wang7, Jinhe Zhang10 and Chunbo Chen1*

© 2018 The Author(s)

Abstract

Purpose: To determine whether erythromycin is non-inferior to metoclopramide in facilitating post-pyloric placement of self-propelled spiral nasoenteric tubes (NETs) in critically ill patients.

Methods: A prospective, multicenter, open-label, parallel, and non-inferiority randomized controlled trial was conducted comparing erythromycin with metoclopramide in facilitating post-pyloric placement of spiral NETs in critically ill patients admitted to intensive care units (ICUs) of eight tertiary hospitals in China. The primary outcome was procedure success defined as post-pyloric placement (spiral NETs reached the first portion of the duodenum or beyond confirmed by abdominal radiography 24 h after tube insertion).

Results: A total of 5688 patients were admitted to the ICUs. Of these, in 355 patients there was a plan to insert a nasoenteric feeding tube, of whom 332 were randomized, with 167 patients assigned to the erythromycin group and 165 patients assigned to the metoclopramide group. The success rate of post-pyloric placement was 57.5% (96/167) in the erythromycin group, as compared with 50.3% (83/165) in the metoclopramide group (a difference of 7.2%, 95% CI −3.5% to 17.9%), in the intention-to-treat analysis, not including the prespecified margin of −10% for non-inferiority. The success rates of post-D1 (reaching the second portion of the duodenum or beyond), post-D2 (reaching the third portion of the duodenum or beyond), post-D3 (reaching the fourth portion of the duodenum or beyond), and proximal jejunum placement and the incidence of any adverse events were not significantly different between the groups.

Conclusions: Erythromycin is non-inferior to metoclopramide in facilitating post-pyloric placement of spiral NETs in critically ill patients. The success rates of post-D1, post-D2, post-D3, and proximal jejunum placement were not significantly different.

Keywords: Self-propelled nasoenteric tubes, Post-pyloric placement, Prokinetic agents, Erythromycin, Metoclopramide, Critically ill patients

*Correspondence: gghccm@163.com

1 Department of Intensive Care Unit of Cardiovascular Surgery, Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 96 Dongchuan Road, Guangzhou 510080, Guangdong, China

Full author information is available at the end of the article.

Bei Hu, Xin Ouyang, and Liming Lei contributed equally to this study.
Introduction

Enteral nutrition (EN) via tube feeding is the preferred way of feeding critically ill patients who are unable to have adequate oral intake. Existing guidelines recommend post-pyloric feeding in patients deemed to be at high risk for aspiration or intolerant of intragastric feeding [1–3]. Using a self-propelled spiral nasoenteric tube (NET) for post-pyloric feeding of critically ill patients has emerged as an alternative approach [4–6], especially when endoscopic and fluoroscopic assistance is limited. Spiral NET is designed to utilize peristalsis to pass the tip through the pylorus and on into the duodenum and jejunum [7]. Thus, using prokinetic agents to facilitate transpyloric migration is a sensible strategy, and a randomized controlled trial (RCT) had demonstrated that metoclopramide could improve the success rate of post-pyloric placement of spiral NETs compared with a control group without promotility agents (55.0% vs. 27.3%, \( P=0.0001 \)) [6]. Although several studies of the ability of erythromycin to promote post-pyloric placement of spiral or straight-ended NETs have been reported [8–13], there is limited evidence that erythromycin, as a common prokinetic medication, facilitates transpyloric migration of spiral NETs in critically ill patients.

Therefore, a non-inferiority RCT was designed to assess whether erythromycin is non-inferior to metoclopramide in facilitating post-pyloric placement of spiral NETs in critically ill adults.

Methods

Trial design

This was a prospective, multicenter, open-label, parallel, and non-inferiority RCT performed in the intensive care units (ICUs) of eight tertiary hospitals in China. The study design, which was planned in accordance with the CONSORT statement [14], was approved by the ethic committees of each participating center and was conducted according to the Declaration of Helsinki. Written informed consent was obtained from each patient or their legal surrogates. The trial was registered at [http://www.chictr.org.cn](http://www.chictr.org.cn) (registration number ChiCTR-INR-16008211).

Patients

Between October 2016 and July 2018, all patients consecutively admitted to ICUs, at least 18 years old, requiring EN, and with elevated gastric residual (single measurement greater than 150 mL or 12 h cumulative volume greater than 500 mL) [15] were recruited. Exclusion criteria included the presence of an indication for percutaneous gastrostomy or jejunostomy; esophageal varices or history of major gastroesophageal surgery (e.g., esophagectomy or gastrectomy); active upper gastrointestinal bleeding; severe nasopharyngeal injuries or stenosis; severe coagulopathy; gastric malignancy, gastrointestinal ulcer, or occlusive ileus; pregnancy; contraindications of erythromycin or metoclopramide; and history of allergy to meglumine diatrizoate.

Eligible patients were randomly assigned to erythromycin or metoclopramide arms at a 1:1 ratio by computer-generated random numbers in blocks of eight to minimize the allocation bias. Each center telephoned the randomization center to verify the groups. None of the investigators was aware of the randomization list prior to group allocation, nor block numbers or block sizes at any moment.

Study intervention

A 145-cm-long, self-propelled spiral NET (CH10, Flocare Bengmark, Nutricia, Wuxi, China) that was made of radiopaque polyurethane was used in this study. According to the manufacturer’s instructions, the feeding tube was inserted in the supine position, with the head tilted at 30°. The tube was straightened using the stylet, and the tube and stylet lumen were lubricated with paraffin. The tube was then inserted 50–55 cm down into the larger nostril. The position was confirmed by air injection into the stomach. The stylet was then pulled out by approximately 25 cm with gentle tugs until loose, and the tube was inserted down 75–80 cm. Before removing the stylet, the position of the tube was again confirmed. Then the stylet was removed and the tube was fixed on the patient’s face with a free loop of approximately 40 cm to allow migration.

According to the trial protocol, patients allocated to the metoclopramide group received 20 mg (or 10 mg in cases of renal insufficiency) metoclopramide intravenously 10 min before tube insertion. In the erythromycin group, 500 mg of erythromycin dissolved in 100 mL of 0.9% saline was given intravenously 30 min before insertion and again every 6 h for 24 h once the tube was in the stomach.
Data collection
Once patients were enrolled, data including demographic characteristics, diagnosis, concomitant medication, and severity of illness including the Acute Physiology and Chronic Health Evaluation II (APACHE II) score, Sequential Organ Failure Assessment (SOFA) score, and Acute Gastrointestinal Injury (AGI) grade were collected. The tube tip position confirmed by abdominal radiography 24 h after tube insertion, which was reviewed by an expert group of intensivists and radiologists blinded to this study, was also recorded. If the tube position was difficult to review (e.g., in patients with obesity or gastrointestinal distension), an additional hydrosoluble contrast injection of meglumine diatrizoate was administered via the tube before radiography. The exact location of the tube tips was documented, including the stomach, first (D1), second (D2), third (D3), and fourth (D4) portions of the duodenum, and proximal jejunum. Adverse event data regarding the side effects of study drugs and tube insertion complications were also assessed and recorded. Types of ICU-acquired infections (IAIs, defined as new infections acquired no less than 48 h after ICU admission), infection time points, and isolated microorganisms were documented in the hospital infection monitoring system and transcribed by an expert group of intensivists and infection control staff blinded to this study.

Study outcomes
The primary outcome was procedure success defined as post-pyloric placement (spiral NETs reached the first portion of the duodenum or beyond confirmed by abdominal radiography 24 h after tube insertion). The a priori defined secondary outcome parameters were the success rate of post-D1 (reaching the second portion of the duodenum or beyond), post-D2 (reaching the third portion of the duodenum or beyond), post-D3 (reaching the fourth portion of the duodenum or beyond), and proximal jejunum placement 24 h after tube insertion.

Adverse events
We assessed safety on the basis of the occurrence of study drug side effects, tube insertion complications, and new IAIs (defined as IAIs acquired no less than 48 h after the procedure). Multiple adverse events per patient were analyzed as a single event.

Statistical analysis
On the basis of the findings of previous RCTs, we estimated the procedure success rate to be 61% [12] in the erythromycin group and 55% [6] in the metoclopramide group. Assuming a non-inferiority margin of −10% as clinically acceptable, with a one-sided type I error of 2.5%, a sample size of 149 patients per group calculated by PASS software (version 13.0) would be required to obtain a statistical power \((1 − \beta)\) of 80%. Considering a 10% dropout rate, at least 332 participants were expected to be recruited for the study. To assess for non-inferiority, we used hypothesis testing (one-sided \(\mu\) test) and derivation of a two-sided 95% confidence interval (CI), where non-inferiority is assumed, if the \(P\) value of the test was less than 0.025 and the lower limit of the 95% CI for the difference in procedure success rate exceeded −10%.

The data of categorical variables were reported as number (percentage), as the means ± standard deviations for continuous variables with normal distribution, and as medians (interquartile ranges) for continuous variables with skewed distribution. The Shapiro–Wilk test was used to detect the normality of data distributions. We used the \(\chi^2\) or Fisher exact test for categorical variables and the \(t\) test or Mann–Whitney U test for continuous variables according to the distribution to compare the data between two groups. We assessed the study outcomes by intention-to-treat (ITT) analysis and all randomized patients were included in the ITT set. All \(P\) values were two-sided except in the test of non-inferiority and were considered statistically significant if the \(P\) value was less than 0.05. Statistical analysis was performed using SPSS 20.0 (SPSS Inc., Chicago, IL, USA) and SAS 9.4 (SAS Inc., Cary, NC, USA).

Results
Enrollment
A total of 5688 patients were admitted to ICUs. Of these, in 355 patients there was a plan to insert a nasointeric feeding tube, of whom 332 were randomized, with 167 patients assigned to the erythromycin group and 165 patients assigned to the metoclopramide group (Fig. 1).

Baseline characteristics
The randomized patients’ baseline data listed in Table 1 were well balanced between the erythromycin group and metoclopramide group. Most patients admitted to the ICU were diagnosed with nervous system diseases, accounting for 62% of the total. More than half of the patients were treated with mechanical ventilation in both groups. There were no differences in the frequency of use of sedatives, vasopressors, or mechanical ventilation. No significant differences in APACHE II score, SOFA score, or AGI grade were found between the two groups (\(P > 0.05\)).

Primary outcomes
In the ITT population, there were 96 patients [96/167 (57.5%)] confirmed with successful post-pyloric placement 24 h after insertion in the erythromycin group and 83 patients [83/165 (50.3%)] in the metoclopramide group.
group, and the procedure success rates were not significantly different between the two groups ($P = 0.189$) (Fig. 2). The erythromycin group fulfilled the criteria for non-inferiority to the metoclopramide group in the ITT analysis. The null hypothesis of inferiority of the erythromycin group to the metoclopramide group was rejected (a difference of 7.2%, 95% CI $-3.5%$ to $17.9%$, one-sided $P < 0.001$) in the ITT analysis. Moreover, the prespecified
margin of −10% was not included in the 95% CI for the difference of the procedure success rate from the metoclopramide group, as shown in Fig. 2. The erythromycin group was not superior to the metoclopramide group because the lower limit of the same CI was less than zero.

### Secondary outcomes

In the erythromycin group, tube tips were confirmed to reach D1 in 7 patients (4.2%), D2 in 17 patients (10.2%), D3 in 33 patients (19.8%), D4 in 18 patients (10.8%), and the proximal jejunum in 21 patients (12.6%). Correspondingly, the tube tips were confirmed to reach D1 in 8 patients (4.8%), D2 in 14 patients (8.5%), D3 in 24 patients (14.5%), D4 in 14 patients (8.5%), and the proximal jejunum in 23 patients (13.9%) in the metoclopramide group. The proportion of patients achieving post-D1, post-D2, post-D3, and proximal jejunum was not significantly different between the two groups ($P>0.05$) (Fig. 2).

### Safety

No significant differences were observed in the incidence of any adverse events between the erythromycin group and metoclopramide group according to all documented complications on the agents and tubes within 24 h after tube insertion and new IAI information (OR 1.3; 95% CI 0.8–2.0; $P=0.313$) (Table 2). In this study, the rate of tube insertion complications was not significantly different between the groups, but the rate of drug side effects in the erythromycin group (11.4%) was higher than that in the metoclopramide group (2.4%) (OR 5.2; 95% CI 1.7–15.5; $P=0.001$). In addition, diarrhea and liver dysfunction were the most common drug side effects in the erythromycin group, while there were none in the metoclopramide group, and these symptoms were resolved quickly. No tube insertion complications occurred except for nasal mucosa bleeding in 10 patients (3.0%), airway misplacement in 8 patients (2.4%), and bucking in 3 patients (0.9%). Bleeding stopped spontaneously without any treatment, the tube was pulled out immediately.

### Table 1 Baseline characteristics of trial participants

| Variables            | Erythromycin group (n=167) | Metoclopramide group (n=165) | P value |
|----------------------|-----------------------------|------------------------------|---------|
| Age (years)          | 55.7 ± 17.9                 | 58.7 ± 16.7                  | 0.109   |
| Male                 | 114 (68.3)                  | 115 (69.7)                   | 0.778   |
| Primary diagnosis    |                             |                              |         |
| Neurologic           | 109 (65.3)                  | 97 (58.8)                    | 0.224   |
| Respiratory          | 18 (10.8)                   | 17 (10.3)                    | 0.888   |
| Gastrointestinal     | 13 (7.8)                    | 13 (7.9)                     | 0.974   |
| Multitrauma          | 7 (4.2)                     | 7 (4.2)                      | 0.982   |
| Sepsis               | 3 (1.8)                     | 6 (3.6)                      | 0.488   |
| Cardiovascular       | 2 (1.2)                     | 7 (4.2)                      | 0.171   |
| Other                | 15 (9.0)                    | 18 (10.9)                    | 0.557   |
| Use of sedatives     | 53 (31.7)                   | 61 (37.0)                    | 0.315   |
| Use of vasopressors  | 36 (21.6)                   | 31 (18.8)                    | 0.530   |
| Ventilation          | 105 (62.9)                  | 108 (65.5)                   | 0.624   |
| APACHE II score      | 21 (16–25)                  | 21 (17–25)                   | 0.592   |
| SOFA score           | 8 (6–10)                    | 8 (7–10)                     | 0.320   |
| AGI grade            |                             |                              | 0.475   |
| I                    | 93 (55.7)                   | 83 (50.3)                    |         |
| II                   | 56 (33.5)                   | 67 (40.6)                    |         |
| III                  | 18 (10.8)                   | 15 (9.1)                     |         |

Data presented as mean ± standard deviation, median (interquartile range), or n (%) unless indicated otherwise.

APACHE Acute Physiology and Chronic Health Evaluation, SOFA Sequential Organ Failure Assessment, AGI Acute Gastrointestinal Injury.
Erythromycin, a macrolide antibiotic, is another prokinetic agent that has agonistic effects on the motilin receptor located on smooth muscle cells of the antrum and upper duodenum [9, 12], which initiates gastric interdigestive migrating motor complexes (MMCs) that are responsible for the gastric emptying of indigestible particles [22–24]. Previous studies indicated that MMCs presented a dose-dependent response to erythromycin in humans [12, 25], and the dose of erythromycin varied greatly in different post-pyloric placement trials [26, 27]. Thus, 2 g of erythromycin was ultimately chosen on the basis of the dose-dependent property and reference to the drug instruction, although higher doses are available and usually adopted to control Legionella infection. The known phenomenon tachyphylaxis is desensitization of the motilin receptor [28, 29], which is rapidly induced after repeated doses and prolonged length of erythromycin and results in a rapid loss of the prokinetic effects [9, 30, 31]. In addition, in our previous study assessing the effect of metoclopramide in post-pyloric placement of spiral NETs, the primary observational time point used was 24 h after tube insertion. Therefore, the initial 24 h after insertion was adopted in the present study. As a result, our post-pyloric tube placement success rate of 57.5% was similar to findings in previous RCTs using a prescribed erythromycin protocol [9, 12], which was non-inferior to metoclopramide.

In terms of safety, serious adverse events were not explicitly reported in various RCTs on erythromycin or metoclopramide [27]. Although serious complications requiring special treatment were absent in our study, 54 patients (32.3%) in the erythromycin group and 45 (27.3%) in the metoclopramide group encountered medication side effects, tube insertion complications, or new IAIs. However, the incidence of diarrhea and liver dysfunction in the erythromycin group was higher than that in the metoclopramide group, which may be attributed to their different pharmacological properties.

Concern about use of erythromycin, a conventional antibiotic, has been expressed because of its role in altering native bacterial flora and increasing the risk of inducing drug-resistant bacteria, particularly Streptococcus pneumoniae [32, 33]. Therefore, we strictly followed up members of two groups and faithfully recorded information on new IAIs. Makkar et al. [34] found no significant differences between three groups randomized to receive erythromycin, metoclopramide, or placebo. Similarly, no significant differences in new IAIs were observed between the two study groups. Furthermore, we detected that the new MDR IAI rate did not increase in the erythromycin group compared to that in the metoclopramide

once airway misplacement or bucking occurred, and no adverse effect occurred. Moreover, new multidrug-resistant (MDR) IAIs occurred in 12 patients (7.2%) in the erythromycin group vs. 18 patients (10.9%) in the metoclopramide group. Similarly, symptoms of post-D1, post-D2, post-D3, and proximal jejunum placement were not statistically different between the groups.

Erythromycin and metoclopramide, suggested to be initiated in patients with intolerance to enteral feeding or at high risk of aspiration by major guidelines [3, 16], are frequently used as prokinetic agents to promote motility in the ICU. As a specific antagonist of D2 (dopamine) receptors, metoclopramide was frequently introduced in the procedure of post-pyloric placement in recent studies [17–21]. Given that the effect of metoclopramide has been established in post-pyloric placement of NETs in a previous study, we deemed that patients enrolled should not be left untreated according to ethical principles. Thus, no control group without promotility agents was used. In this trial, patients who received the same dosage and use of metoclopramide as in our previous trial had a 50.3% procedure success rate.

Table 2 Adverse events

| Event                      | Erythromycin group (n = 167) | Metoclopramide group (n = 165) | P value |
|----------------------------|------------------------------|--------------------------------|---------|
| Any event                  | 54 (32.3)                    | 45 (27.3)                      | 0.313   |
| Drugs side effects         | 19 (11.4)                    | 4 (2.4)                        | 0.001   |
| Diarrhea                   | 10 (6.0)                     | 0                              | 0.004   |
| Liver dysfunction          | 9 (5.4)                      | 0                              | 0.007   |
| Nausea                     | 2 (1.2)                      | 2 (1.2)                        | 1.000   |
| Vomiting                   | 2 (1.2)                      | 0                              | 0.499   |
| Debilitation               | 1 (0.6)                      | 1 (0.6)                        | 1.000   |
| Rash                       | 1 (0.6)                      | 1 (0.6)                        | 1.000   |
| Arrhythmia                 | 1 (0.6)                      | 0                              | 1.000   |
| Jaundice                   | 1 (0.6)                      | 0                              | 1.000   |
| Dizziness                  | 0                            | 1 (0.6)                        | 0.497   |
| Tube insertion complications| 10 (6.0)                     | 10 (6.1)                       | 0.978   |
| Airway misplacement        | 5 (3.0)                      | 3 (1.8)                        | 0.733   |
| Nasal mucosa bleeding      | 3 (1.8)                      | 7 (4.2)                        | 0.326   |
| Bucking                    | 2 (1.2)                      | 1 (0.6)                        | 1.000   |
| New IAIs                   | 34 (20.4)                    | 35 (21.2)                      | 0.848   |
| New MDR IAIs              | 12 (7.2)                     | 18 (10.9)                      | 0.237   |

Data presented as n (%) unless indicated otherwise
IAIs ICU-acquired infections, MDR multidrug-resistant

Discussion

Erythromycin is non-inferior to metoclopramide in facilitating post-pyloric placement of a self-propelled spiral NET in critically ill adults. Furthermore, the success rates of post-D1, post-D2, post-D3, and proximal jejunum placement were not statistically different between the groups.

Erythromycin and metoclopramide, suggested to be initiated in patients with intolerance to enteral feeding or at high risk of aspiration by major guidelines [3, 16], are frequently used as prokinetic agents to promote motility in the ICU. As a specific antagonist of D2 (dopamine) receptors, metoclopramide was frequently introduced in the procedure of post-pyloric placement in recent studies [17–21]. Given that the effect of metoclopramide has been established in post-pyloric placement of NETs in a previous study, we deemed that patients enrolled should not be left untreated according to ethical principles. Thus, no control group without promotility agents was used. In this trial, patients who received the same dosage and use of metoclopramide as in our previous trial had a 50.3% procedure success rate.

Erythromycin, a macrolide antibiotic, is another prokinetic agent that has agonistic effects on the motilin receptor located on smooth muscle cells of the antrum and upper duodenum [9, 12], which initiates gastric interdigestive migrating motor complexes (MMCs) that are responsible for the gastric emptying of indigestible particles [22–24]. Previous studies indicated that MMCs presented a dose-dependent response to erythromycin in humans [12, 25], and the dose of erythromycin varied greatly in different post-pyloric placement trials [26, 27]. Thus, 2 g of erythromycin was ultimately chosen on the basis of the dose-dependent property and reference to the drug instruction, although higher doses are available and usually adopted to control Legionella infection. The known phenomenon tachyphylaxis is desensitization of the motilin receptor [28, 29], which is rapidly induced after repeated doses and prolonged length of erythromycin and results in a rapid loss of the prokinetic effects [9, 30, 31]. In addition, in our previous study assessing the effect of metoclopramide in post-pyloric placement of spiral NETs, the primary observational time point used was 24 h after tube insertion. Therefore, the initial 24 h after insertion was adopted in the present study. As a result, our post-pyloric tube placement success rate of 57.5% was similar to findings in previous RCTs using a prescribed erythromycin protocol [9, 12], which was non-inferior to metoclopramide.

In terms of safety, serious adverse events were not explicitly reported in various RCTs on erythromycin or metoclopramide [27]. Although serious complications requiring special treatment were absent in our study, 54 patients (32.3%) in the erythromycin group and 45 (27.3%) in the metoclopramide group encountered medication side effects, tube insertion complications, or new IAIs. However, the incidence of diarrhea and liver dysfunction in the erythromycin group was higher than that in the metoclopramide group, which may be attributed to their different pharmacological properties.

Concern about use of erythromycin, a conventional antibiotic, has been expressed because of its role in altering native bacterial flora and increasing the risk of inducing drug-resistant bacteria, particularly Streptococcus pneumoniae [32, 33]. Therefore, we strictly followed up members of two groups and faithfully recorded information on new IAIs. Makkar et al. [34] found no significant differences between three groups randomized to receive erythromycin, metoclopramide, or placebo. Similarly, no significant differences in new IAIs were observed between the two study groups. Furthermore, we detected that the new MDR IAI rate did not increase in the erythromycin group compared to that in the metoclopramide
group. It is noteworthy that this study was not designed and might be unable to detect differences based on new IAI results. Thus, this presentation may indicate to some extent that erythromycin used in the short term would not increase the IAI rate.

Although the present trial demonstrated that erythromycin is non-inferior to metoclopramide, it should be noted that indications and contraindications of the two agents may be different. In addition, patients in the erythromycin group were infused with 400 mL more fluid intravenously than were those in the metoclopramide group. Therefore, more attention should be paid to critically ill patients requiring restricted fluid infusion when prescribing erythromycin. We believe that critically ill patients may benefit from a wealth of choices derived from the evidence of this study, especially in highly heterogeneous ICU settings.

To our knowledge, the current study is the largest RCT to date evaluating whether erythromycin is non-inferior to metoclopramide in assisting transpyloric passage of self-propelled spiral NETs in critically ill patients. In the present trial, the failure rates of both groups were approximately 50%, and prokinetic agents showed less-than-satisfactory effects in facilitating post-pyloric placement of spiral NETs. However, a recent study reported that blind bedside post-pyloric placement of a spiral NET following a special procedure, as a rescue therapy subsequent to failed spontaneous post-pyloric migration, achieved an 81.9% post-pyloric placement success rate [5]. Thus, we speculate that the overall expected success rate can be elevated to over 90% when combining both prokinetic agents and rescue therapy [35]. To demonstrate our perspective, a new clinical trial combining both prokinetic agents and rescue therapy has been registered at http://www.chictr.org.cn (registration number ChiCTR-INR-16009099). Although alternative bedside methods exist, including endoscopic and electromagnetic guidance post-pyloric placement, and the success rate tends to exceed 90% [36, 37], we believe that this trial enriches the choice for transpyloric placement in a timely manner, especially when resources are limited to access. Given that recent studies have indicated that early EN is associated with improved outcomes [38, 39], our trial may contribute to a better implementation of safe and effective early feeding in patients with critical illness.

Our trial has certain limitations. First, the study was not double-blinded because of the different dosage regimens and the appearance of the two agents. To minimize the potential bias, randomization and adequate allocation concealment were adopted in the trial, and the primary and secondary outcomes were objective rather than subjective. Second, over 60% of the patients in our trial were primarily diagnosed with neurologic diseases. Therefore, the generalization of our conclusions to all critically ill patients may be limited. Third, the effect of the prokinetic agents when using other self-propelling tubes remains unanswered. Thus, further studies should be performed to enhance the reliability and external validity of the present research conclusions. Finally, some core outcome measures in critical care nutrition research were not measured and reported in the present trial [40].

Conclusions

Our trial indicates that erythromycin is non-inferior to metoclopramide in facilitating post-pyloric placement of spiral NETs in critically ill patients. The success rates of post-D1, post-D2, post-D3, and proximal jejunum placement were not significantly different. Therefore, erythromycin might be effectively and safely used as an alternative to metoclopramide in facilitating post-pyloric placement of spiral NETs in critically ill patients.
Compliance with ethical standards

Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the ethics committee of the Guangdong General Hospital and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent
Informed consent was obtained from all individual participants included in the study.

Conflicts of interest
The authors declare that they have no conflict of interest.

Open Access
This article is distributed under the terms of the Creative Commons Attribution NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Received: 16 August 2018 Accepted: 13 November 2018 Published online: 21 November 2018

References
1. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubendfeld GD, Angus DC, Arnete D, Beale R, Belliogna GL, Bernard GR, Chiche JD, Cooperink M, De Backer DP, French CJ, Fujijsima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karmok DR, Klenpm RM, Koh Y, Lisaoba TC, Machado FR, Marin JJ, Marshall JC, Mazuki JS, Mcintyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalese P, Nishida O, Osborn TM, Perrier A, Plunkett CM, Rannier M, Schorr CA, Sequel MA, Seymour CM, Shieh L, Shukli KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van den Poel T, Vincent JL, Wiersinga V, Zimmerman JL, Dellinger RP (2017) Surviving Sehispic Campagin: international guidelines for management of sepsis and septic shock. 2016. Intensive Care Med 43:304–377
2. Reintam Blaser A, Storkopf J, Alhazzani W, Berger MM, Cajaer MP, Deane AM, Frinhwalt S, Hiersmayr M, Ichai K, Jakob SM, Louden CL, Malbrant MI, Montejo Gonzalez JC, Paugam-Burtz C, Pezoe M, Preiser JC, Singer P, Van den Poel T, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP (2017) Early enteral nutrition in critically ill patients: ESPC mclni- cal practice guidelines. Intensive Care Med 43:380–398
3. McClave SA, Teilert BE, Martindale RG, Warren MM, Johnson DR, Braunsweg C, McCarthy MS, Davanos E, Rice TW, Cress GA, Gervasio JM, Sacks GS, Roberts PR, Compere CE. Society of Critical Care Medicine, American Society for Parenteral and Enteral Nutrition (2016) Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: society of critical care medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N). JPN J Parenter Enteral Nutr 40:159–211
4. Chen W, Sun C, Wei R, Zhang Y, Ye H, Chi R, Zhang Y, Hu B, Lv B, Chen L, Zhang X, Lan H, Chen C (2018) Establishing decision trees for predicting successful post pyloric nasoenteric tube placement in critically ill patients. JPN J Parenteral Enteral Nutr 40:159–211
5. Lv B, Hu L, Chen L, Hu B, Zhang Y, Ye H, Sun C, Zhang X, Lan H Chen C (2012) Blind bedside postpyloric placement of spiral tube as rescue therapy in critically ill patients: a prospective, trienctic, observational study. Crit Care 21:248
6. Hu B, Ye H, Sun C, Zhang Y, Lao Z, Wu F, Liu Z, Huang L, Qu C, Xian L, Wu H, Jiao Y, Liu J, Cai J, Chen W, Nie Z, Liu Z, Chen C (2015) Metoclopramide or domperidone improves post-pyloric placement of spiral nasojugal tubes in critically ill patients: a prospective, multicenter, open-label, randomized, controlled clinical trial. Crit Care 1961
prokinetic agents in critically ill patients receiving enteral nutrition: a systematic review and meta-analysis of randomized trials. Crit Care 20:259

28. Lamian V, Rich A, Ma Z, Li J, Seethala R, Gordon D, Dubaque Y (2006) Characterization of agonist-induced motilin receptor trafficking and its implications for tachyphylaxis. Mol Pharmacol 69:109–118

29. Thielemans L, Depoortere I, Perret J, Robberecht P, Liu Y, Thijs T, Carreras C, Burgeon E, Peeters TL (2005) Desensitization of the human motilin receptor by motilides. J Pharmacol Exp Ther 313:1397–1405

30. Bernes JD, Norwood SH, McAuley CE, Vallina VL, Vilereal D, Weston J, McClyrty J (2002) Erythromycin reduces delayed gastric emptying in critically ill trauma patients: a randomized, controlled trial. J Trauma 53:422–425

31. Chapman MJ, Fraser RJ, Kluger MT, Buist MD, De Nichilo DJ (2000) Erythromycin improves gastric emptying in critically ill patients intolerant of nasogastric feeding. Crit Care Med 28:2334–2337

32. Hawkyard CV, Koerner RJ (2007) The use of erythromycin as a gastrointestional prokinetic agent in adult critical care: benefits versus risks. J Antimicrob Chemother 59:347–358

33. Dall’Antonia M, Wilks M, Coen PG, Bragman S, Millar MR (2006) Erythromycin for prokinesis: imprudent prescribing? Crit Care 10:112

34. Makkar JK, Gauli B, Jain K, Jain D, Batra Y (2016) Comparison of erythromycin versus metoclopramide for gastric feeding intolerance in patients with traumatic brain injury: a randomized double-blind study. Saudi J Anaesth 10:308–313

35. Hu B, Lv B, Chen C (2018) The choice of a postpyloric tube and the patient’s position in our procedure: a response. Crit Care 22:127

36. Gerritsen A, van der Poel MJ, de Rooij J, Molenzaar IJ, Bergman JJ, Busch OR, Mathus-Vliegen EM, Besselink MG (2015) Systematic review on bedside electromagnetic-guided, endoscopic, and fluoroscopic placement of nasoenteral feeding tubes. Gastrointest Endosc 81:836–847.e832

37. Mathus-Vliegen EM, Duflou A, Spanier MB, Fockens P (2010) Nasoenteral feeding tube placement by nurses using an electromagnetic guidance system (with video). Gastrointest Endosc 71:729–736

38. Ohbe H, Jo T, Yamana H, Matsu H, Fushimi K, Yasunaga H (2018) Early enteral nutrition for cardiogenic or obstructive shock requiring venoarterial extracorporeal membrane oxygenation: a nationwide inpatient database study. Intensive Care Med 44:1258–1265

39. Prakash V, Parameswaran N, Bswal N (2016) Early versus late enteral feeding in critically ill children: a randomized controlled trial. Intensive Care Med 42:481–482

40. Arabi YM, Preiser JC (2017) A critical view on primary and secondary outcome measures in nutrition trials. Intensive Care Med 43:1875–1877